← Back to Calendar

Bicycle Therapeutics Q4 2025 Earnings

Bicycle Therapeutics · $BCYC

Standard Review Earnings

PDUFA Date

March 10, 2026

Time Remaining

14d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + BT8009 DUET-2 update

Key Notes

Q4 2025 earnings reported March 10, 2026. Update on BT8009 DUET-2 Phase 2 trial in metastatic urothelial carcinoma — data expected Q3 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar